ERBB2 and breast cancer: Additionally, studies of HER2 expression in CMTs using IHC with an FDA-approved anti-HER2 polyclonal antibody (A0485, Dako, Glostrup, Denmark) revealed differences in the expression patterns and non-specific cytoplasmic staining patterns in accordance with the criteria for human breast cancer [18, 19].